Vanguard Capital Management
PLYX

Vanguard Capital Management’s Polaryx Therapeutics Inc PLYX Stock Holding History

Vanguard Capital Management’s Portfolio PLYX Stock Details PLYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.41M Sell
1,657,872
-516
-0% -$2.02K ﹤0.01% 3170
2026
Q1 		$12.5M Buy
+1,658,388
New +$10.7M ﹤0.01% 2609

Other funds holding PLYX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Vanguard Global Advisers
Vanguard Global Advisers Malvern, Pennsylvania $215B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's PLYX Position: Q2 2026 in Review

Vanguard Capital Management reduced its Polaryx Therapeutics Inc (PLYX) stake by 0.03% in Q2 2026, selling an estimated $2.02K and leaving 1,657,872 shares worth $4.41M. The position accounts for ﹤0.01% of the portfolio, ranked #3170.

Vanguard Capital Management first reported a position in PLYX in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.5M in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

  • Vanguard Capital Management held 1,657,872 shares of Polaryx Therapeutics Inc worth $4.41M as of Q2 2026.
  • Vanguard Capital Management sold 516 Polaryx Therapeutics Inc shares in Q2 2026, an estimated $2.02K.
  • Polaryx Therapeutics Inc made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3170 holding.
  • Vanguard Capital Management first reported a position in Polaryx Therapeutics Inc in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Polaryx Therapeutics Inc position peaked at $12.5M in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.